Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itri

Showing results (311-320 of 323) with videos related to

Pageof 33
Sort By:
Cancer|March 20, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Therapeutic Advances in Hematology|March 16, 2023
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registryMonia Marchetti, Jon Salmanton-García, Shaimaa El-Ashwah, et al.
Frontiers in Immunology|March 13, 2023
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registryAlessandro Busca, Jon Salmanton-García, Francesco Marchesi, et al.
International Journal of Antimicrobial Agents|August 15, 2023
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Philipp Koehler, et al.
Leukemia & Lymphoma|November 15, 2023
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA surveyShaimaa El-Ashwah, Jon Salmanton-García, Yavuz M Bilgin, et al.
Frontiers in Oncology|October 24, 2022
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, et al.
Eclinicalmedicine|April 12, 2023
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Maria Gomes da Silva, et al.
Cancers|November 26, 2022
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha SurveyChiara Cattaneo, Jon Salmanton-García, Francesco Marchesi, et al.
Blood|September 20, 2022
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA surveyLivio Pagano, Jon Salmanton-García, Francesco Marchesi, et al.
Hematological Oncology|December 5, 2023
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registryPellegrino Musto, Jon Salmanton-García, Nicola Sgherza, et al.
Pageof 33

Showing results (311-320 of 323) with videos related to

Sort By:
Pageof 33
Cancer|March 20, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Therapeutic Advances in Hematology|March 16, 2023
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registryMonia Marchetti, Jon Salmanton-García, Shaimaa El-Ashwah, et al.
Frontiers in Immunology|March 13, 2023
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registryAlessandro Busca, Jon Salmanton-García, Francesco Marchesi, et al.
International Journal of Antimicrobial Agents|August 15, 2023
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Philipp Koehler, et al.
Leukemia & Lymphoma|November 15, 2023
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA surveyShaimaa El-Ashwah, Jon Salmanton-García, Yavuz M Bilgin, et al.
Frontiers in Oncology|October 24, 2022
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, et al.
Eclinicalmedicine|April 12, 2023
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Maria Gomes da Silva, et al.
Cancers|November 26, 2022
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha SurveyChiara Cattaneo, Jon Salmanton-García, Francesco Marchesi, et al.
Blood|September 20, 2022
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA surveyLivio Pagano, Jon Salmanton-García, Francesco Marchesi, et al.
Hematological Oncology|December 5, 2023
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registryPellegrino Musto, Jon Salmanton-García, Nicola Sgherza, et al.
Pageof 33